This regulatory network was inferred from the input dataset. The miRNAs and mRNAs are
presented as round and rectangle nodes respectively. The numerical value popped up upon mouse over the gene node is the log2 transformed fold-change of the gene expression between the two groups. All of the nodes are clickable, and the detailed information of the miRNAs/mRNAs and related cancer pathway will be displayed in another window. The edges between nodes are supported by both interactions (predicted or experimentally verified) and correlations learnt from cancer dataset. The numerical value popped up upon mouse over the edge is the correlation beat value (effect size) between the two nodes. The experimental evidences of the edges reported in previous cancer studies are highlighted by red/orange color. All of these information can be accessed by the "mouse-over" action. This network shows a full map of the miRNA-mRNA regulation of the input gene list(s), and the hub miRNAs (with the high network degree/betweenness centrality) would be the potential cancer drivers or tumor suppressors. The full result table can be accessed in the "Regulations" tab.
"miRNACancerMAP" is also a network visualization tool for users to draw their regulatory network by personal customization. Users can set the complexity of the network by limiting the number of nodes or edges. And the color of the nodes can be defined by different categories of the mRNAs and miRNAs, such as Gene-Ontology, pathway, and expression status. Users can also select to use network degree or network betweenness centrality to define the node size. And edges can be black or colored by the correlation. Purple edge means negative correlation (mostly found between miRNA and mRNA), and blue edge means positive correlation (found in PPI or miRNA-miRNA sponge effect). We can also add the protein-protein interactions (PPI) into the network. This result will show the cluster of genes regulated by some specific miRNAs. Additionally, miRNA-miRNA edges can be added by the "miRNA sponge" button, presenting some clusters of miRNAs that have the interactions via sponge effect.
Num | microRNA | Gene | miRNA log2FC | miRNA pvalue | Gene log2FC | Gene pvalue | Interaction | Correlation beta | Correlation P-value | PMID | Reported in cancer studies |
---|---|---|---|---|---|---|---|---|---|---|---|
1 | hsa-miR-17-5p | ABCD2 | 2.33 | 0.30125 | -2.73 | 0.01225 | MirTarget | -0.54 | 0 | NA | |
2 | hsa-miR-17-5p | ABHD2 | 2.33 | 0.30125 | 0.09 | 0.9591 | TargetScan; miRNATAP | -0.18 | 0.00209 | NA | |
3 | hsa-miR-454-3p | ACSL1 | 1.37 | 0.14233 | -0.18 | 0.89649 | MirTarget | -0.21 | 0.00407 | NA | |
4 | hsa-miR-454-3p | ACSL4 | 1.37 | 0.14233 | -0.96 | 0.51944 | MirTarget; miRNATAP | -0.14 | 0.04315 | NA | |
5 | hsa-miR-454-3p | ACVR1 | 1.37 | 0.14233 | -0.76 | 0.54869 | MirTarget; miRNATAP | -0.12 | 0.00599 | NA | |
6 | hsa-miR-17-5p | ACVRL1 | 2.33 | 0.30125 | -3.43 | 0.00079 | TargetScan | -0.23 | 0.0002 | NA | |
7 | hsa-miR-17-5p | ADAMTS5 | 2.33 | 0.30125 | -6.31 | 0 | TargetScan | -0.22 | 0.02546 | NA | |
8 | hsa-miR-17-5p | AFF1 | 2.33 | 0.30125 | -1.07 | 0.49725 | TargetScan | -0.11 | 0.00674 | NA | |
9 | hsa-miR-17-5p | AGFG2 | 2.33 | 0.30125 | -1.28 | 0.29482 | TargetScan; miRNATAP | -0.19 | 1.0E-5 | NA | |
10 | hsa-miR-17-5p | AHNAK | 2.33 | 0.30125 | -1.04 | 0.64703 | TargetScan; miRNATAP | -0.18 | 0.00111 | NA | |
11 | hsa-miR-454-3p | AKAP11 | 1.37 | 0.14233 | -0.66 | 0.63974 | miRNATAP | -0.12 | 0.00898 | NA | |
12 | hsa-miR-17-5p | AKAP13 | 2.33 | 0.30125 | -1.53 | 0.37244 | MirTarget; TargetScan; mirMAP; miRNATAP | -0.19 | 0 | NA | |
13 | hsa-miR-17-5p | AKT3 | 2.33 | 0.30125 | -3.26 | 0.00117 | TargetScan; miRNATAP | -0.17 | 0.02914 | NA | |
14 | hsa-miR-454-3p | AMPD3 | 1.37 | 0.14233 | 1.49 | 0.13818 | MirTarget; miRNATAP | -0.28 | 3.0E-5 | NA | |
15 | hsa-miR-17-5p | ANK2 | 2.33 | 0.30125 | -5.43 | 0 | MirTarget; miRNATAP | -0.6 | 0 | NA | |
16 | hsa-miR-454-3p | ANKRD12 | 1.37 | 0.14233 | -0.46 | 0.71724 | MirTarget; miRNATAP | -0.11 | 0.01667 | NA | |
17 | hsa-miR-17-5p | ANKRD29 | 2.33 | 0.30125 | -2.22 | 0.05518 | MirTarget; TargetScan | -0.54 | 0 | NA | |
18 | hsa-miR-17-5p | ANKRD50 | 2.33 | 0.30125 | 0 | 0.99734 | MirTarget; TargetScan; miRNATAP | -0.16 | 0.00363 | NA | |
19 | hsa-miR-17-5p | ANXA11 | 2.33 | 0.30125 | -0.04 | 0.98232 | mirMAP | -0.11 | 0.00676 | NA | |
20 | hsa-miR-17-5p | AR | 2.33 | 0.30125 | -4.67 | 0.00218 | mirMAP | -0.79 | 0 | 23095762 | miR 17 5p targets the p300/CBP associated factor and modulates androgen receptor transcriptional activity in cultured prostate cancer cells; Targeting of the 3'-untranslated region of PCAF mRNA by miR-17-5p caused translational suppression and RNA degradation and consequently modulation of AR transcriptional activity in PCa cells; Targeting of PCAF by miR-17-5p modulates AR transcriptional activity and cell growth in cultured PCa cells |
21 | hsa-miR-454-3p | AR | 1.37 | 0.14233 | -4.67 | 0.00218 | mirMAP; miRNATAP | -0.47 | 0.00625 | NA | |
22 | hsa-miR-17-5p | ARAP2 | 2.33 | 0.30125 | 1.85 | 0.12177 | MirTarget; TargetScan | -0.14 | 0.01554 | NA | |
23 | hsa-miR-454-3p | ARAP2 | 1.37 | 0.14233 | 1.85 | 0.12177 | MirTarget | -0.2 | 0.00207 | NA | |
24 | hsa-miR-454-3p | ARHGAP21 | 1.37 | 0.14233 | -0.06 | 0.96644 | MirTarget; miRNATAP | -0.14 | 0.01042 | NA | |
25 | hsa-miR-17-5p | ARHGAP24 | 2.33 | 0.30125 | -1.57 | 0.12603 | MirTarget | -0.23 | 0.01058 | NA | |
26 | hsa-miR-17-5p | ARHGAP26 | 2.33 | 0.30125 | -0.19 | 0.90211 | MirTarget; TargetScan; mirMAP; miRNATAP | -0.23 | 0.00209 | NA | |
27 | hsa-miR-17-5p | ARHGAP31 | 2.33 | 0.30125 | -2.29 | 0.00905 | TargetScan | -0.3 | 0 | NA | |
28 | hsa-miR-454-3p | ARHGEF12 | 1.37 | 0.14233 | -0.46 | 0.79305 | MirTarget; miRNATAP | -0.16 | 0.0003 | NA | |
29 | hsa-miR-17-5p | ARHGEF3 | 2.33 | 0.30125 | -1.01 | 0.44523 | MirTarget; TargetScan; miRNATAP | -0.16 | 0.00015 | NA | |
30 | hsa-miR-17-5p | ARL4C | 2.33 | 0.30125 | 1.91 | 0.17875 | MirTarget; TargetScan; miRNATAP | -0.15 | 0.03095 | NA | |
31 | hsa-miR-17-5p | ARSD | 2.33 | 0.30125 | 0 | 0.99908 | mirMAP | -0.32 | 0 | NA | |
32 | hsa-miR-17-5p | ASPA | 2.33 | 0.30125 | -5.59 | 0.00012 | mirMAP | -0.55 | 1.0E-5 | NA | |
33 | hsa-miR-454-3p | ASPA | 1.37 | 0.14233 | -5.59 | 0.00012 | mirMAP | -0.32 | 0.02559 | NA | |
34 | hsa-miR-454-3p | ASXL2 | 1.37 | 0.14233 | 0.94 | 0.44816 | MirTarget; miRNATAP | -0.2 | 0.03105 | NA | |
35 | hsa-miR-17-5p | ASXL3 | 2.33 | 0.30125 | -4.32 | 0.00164 | TargetScan | -0.39 | 0.00638 | NA | |
36 | hsa-miR-17-5p | ATF3 | 2.33 | 0.30125 | -0.68 | 0.67723 | miRNAWalker2 validate | -0.18 | 0.03451 | NA | |
37 | hsa-miR-17-5p | ATOH8 | 2.33 | 0.30125 | -5.62 | 0 | TargetScan | -0.36 | 0.00027 | NA | |
38 | hsa-miR-17-5p | ATP1A2 | 2.33 | 0.30125 | -7.07 | 0 | MirTarget; TargetScan | -0.72 | 0 | NA | |
39 | hsa-miR-454-3p | ATP6V1B2 | 1.37 | 0.14233 | 0.31 | 0.84053 | MirTarget; miRNATAP | -0.1 | 0.00585 | NA | |
40 | hsa-miR-17-5p | ATXN1 | 2.33 | 0.30125 | -1.44 | 0.25265 | TargetScan; miRNATAP | -0.19 | 0.00016 | NA | |
41 | hsa-miR-454-3p | ATXN1 | 1.37 | 0.14233 | -1.44 | 0.25265 | miRNATAP | -0.17 | 0.00303 | NA | |
42 | hsa-miR-17-5p | ATXN7L1 | 2.33 | 0.30125 | -0.26 | 0.74464 | TargetScan | -0.18 | 0 | NA | |
43 | hsa-miR-454-3p | BBX | 1.37 | 0.14233 | -0.17 | 0.90638 | MirTarget; miRNATAP | -0.1 | 0.02182 | NA | |
44 | hsa-miR-17-5p | BCAS1 | 2.33 | 0.30125 | -0.49 | 0.78808 | mirMAP | -0.86 | 0 | NA | |
45 | hsa-miR-17-5p | BCL6 | 2.33 | 0.30125 | -0.43 | 0.75836 | TargetScan | -0.16 | 0.0008 | NA | |
46 | hsa-miR-454-3p | BCL9L | 1.37 | 0.14233 | -0.07 | 0.96468 | mirMAP | -0.14 | 0.00577 | NA | |
47 | hsa-miR-454-3p | BHLHE40 | 1.37 | 0.14233 | 1.11 | 0.56907 | miRNAWalker2 validate | -0.24 | 0.00086 | NA | |
48 | hsa-miR-17-5p | BHLHE41 | 2.33 | 0.30125 | -1.42 | 0.31661 | TargetScan; miRNATAP | -0.44 | 1.0E-5 | NA | |
49 | hsa-miR-17-5p | BICC1 | 2.33 | 0.30125 | -2.29 | 0.08377 | TargetScan | -0.31 | 0.02277 | NA | |
50 | hsa-miR-17-5p | BMPR2 | 2.33 | 0.30125 | -1.14 | 0.45199 | miRNAWalker2 validate; MirTarget; TargetScan; miRNATAP | -0.12 | 0.00049 | NA | |
51 | hsa-miR-17-5p | BNC2 | 2.33 | 0.30125 | -6.05 | 0 | TargetScan; miRNATAP | -0.58 | 0 | NA | |
52 | hsa-miR-454-3p | BRWD3 | 1.37 | 0.14233 | 2.17 | 0.04658 | MirTarget; miRNATAP | -0.2 | 0.01287 | NA | |
53 | hsa-miR-454-3p | BTBD10 | 1.37 | 0.14233 | 0.53 | 0.66167 | MirTarget | -0.18 | 3.0E-5 | NA | |
54 | hsa-miR-17-5p | BTG1 | 2.33 | 0.30125 | -0.79 | 0.64588 | TargetScan | -0.12 | 0.00371 | NA | |
55 | hsa-miR-454-3p | BTG1 | 1.37 | 0.14233 | -0.79 | 0.64588 | miRNATAP | -0.11 | 0.02771 | NA | |
56 | hsa-miR-17-5p | BTG2 | 2.33 | 0.30125 | -1.97 | 0.25098 | TargetScan | -0.11 | 0.04449 | NA | |
57 | hsa-miR-17-5p | BTN3A1 | 2.33 | 0.30125 | -0.3 | 0.82105 | miRNAWalker2 validate | -0.24 | 0.00014 | NA | |
58 | hsa-miR-409-3p | BTN3A2 | 0.28 | 0.79947 | -0.05 | 0.97293 | mirMAP | -0.13 | 0.01301 | NA | |
59 | hsa-miR-17-5p | C14orf28 | 2.33 | 0.30125 | -2.37 | 0.00011 | TargetScan; miRNATAP | -0.23 | 0 | NA | |
60 | hsa-miR-454-3p | C15orf52 | 1.37 | 0.14233 | -1.25 | 0.3319 | mirMAP | -0.36 | 0.00077 | NA | |
61 | hsa-miR-454-3p | C1S | 1.37 | 0.14233 | -1.82 | 0.27315 | MirTarget | -0.25 | 0.01612 | NA | |
62 | hsa-miR-409-3p | C1orf21 | 0.28 | 0.79947 | -1.12 | 0.41646 | PITA; mirMAP | -0.13 | 0.02071 | NA | |
63 | hsa-miR-17-5p | C3orf70 | 2.33 | 0.30125 | -3.26 | 0.00156 | TargetScan | -0.21 | 0.04273 | NA | |
64 | hsa-miR-17-5p | CA10 | 2.33 | 0.30125 | -3.64 | 0.02709 | miRNATAP | -0.33 | 0.02235 | NA | |
65 | hsa-miR-17-5p | CALD1 | 2.33 | 0.30125 | -3.71 | 0.02146 | TargetScan; miRNATAP | -0.21 | 0.00428 | NA | |
66 | hsa-miR-17-5p | CAPN5 | 2.33 | 0.30125 | -1.94 | 0.26998 | mirMAP | -0.37 | 0.00205 | NA | |
67 | hsa-miR-17-5p | CASC4 | 2.33 | 0.30125 | -1.45 | 0.37749 | MirTarget | -0.14 | 0.0007 | NA | |
68 | hsa-miR-17-5p | CBX7 | 2.33 | 0.30125 | -3.22 | 0.00976 | mirMAP | -0.32 | 0 | NA | |
69 | hsa-miR-454-3p | CD109 | 1.37 | 0.14233 | 0.41 | 0.73596 | mirMAP | -0.3 | 0.02391 | NA | |
70 | hsa-miR-17-5p | CD226 | 2.33 | 0.30125 | 0.6 | 0.47807 | TargetScan | -0.32 | 6.0E-5 | NA | |
71 | hsa-miR-17-5p | CD69 | 2.33 | 0.30125 | -0.62 | 0.5233 | TargetScan; miRNATAP | -0.44 | 0 | NA | |
72 | hsa-miR-454-3p | CD69 | 1.37 | 0.14233 | -0.62 | 0.5233 | miRNATAP | -0.25 | 0.01834 | NA | |
73 | hsa-miR-454-3p | CDH11 | 1.37 | 0.14233 | -2.75 | 0.04281 | mirMAP | -0.48 | 7.0E-5 | NA | |
74 | hsa-miR-17-5p | CELF2 | 2.33 | 0.30125 | -2.38 | 0.01903 | TargetScan | -0.3 | 0.00014 | NA | |
75 | hsa-miR-17-5p | CHD9 | 2.33 | 0.30125 | -0.24 | 0.84856 | MirTarget; TargetScan; miRNATAP | -0.17 | 7.0E-5 | NA | |
76 | hsa-miR-454-3p | CHD9 | 1.37 | 0.14233 | -0.24 | 0.84856 | miRNATAP | -0.17 | 0.00054 | NA | |
77 | hsa-miR-17-5p | CHIC1 | 2.33 | 0.30125 | -1.78 | 0.08872 | TargetScan | -0.26 | 5.0E-5 | NA | |
78 | hsa-miR-17-5p | CIITA | 2.33 | 0.30125 | 0.67 | 0.63916 | mirMAP | -0.21 | 0.04302 | NA | |
79 | hsa-miR-17-5p | CLIC6 | 2.33 | 0.30125 | -0.19 | 0.92919 | mirMAP | -0.47 | 0.00962 | NA | |
80 | hsa-miR-454-3p | CLIP1 | 1.37 | 0.14233 | 0.42 | 0.78033 | MirTarget; miRNATAP | -0.21 | 7.0E-5 | NA | |
81 | hsa-miR-409-3p | CLYBL | 0.28 | 0.79947 | -0.96 | 0.26882 | miRNATAP | -0.14 | 0.0173 | NA | |
82 | hsa-miR-17-5p | CMKLR1 | 2.33 | 0.30125 | -2.3 | 0.0139 | TargetScan | -0.35 | 9.0E-5 | NA | |
83 | hsa-miR-17-5p | CNN1 | 2.33 | 0.30125 | -8.99 | 0 | TargetScan | -0.71 | 0 | NA | |
84 | hsa-miR-17-5p | COL1A1 | 2.33 | 0.30125 | -1.82 | 0.45918 | mirMAP | -0.33 | 0.00039 | NA | |
85 | hsa-miR-17-5p | COL8A2 | 2.33 | 0.30125 | -0.42 | 0.72104 | mirMAP | -0.23 | 0.01147 | NA | |
86 | hsa-miR-17-5p | CORO2B | 2.33 | 0.30125 | -3.77 | 0.00099 | MirTarget; TargetScan; miRNATAP | -0.33 | 0.00536 | NA | |
87 | hsa-miR-454-3p | CPEB2 | 1.37 | 0.14233 | -0.45 | 0.66859 | miRNATAP | -0.16 | 0.01428 | NA | |
88 | hsa-miR-17-5p | CPEB3 | 2.33 | 0.30125 | -0.09 | 0.91502 | TargetScan; miRNATAP | -0.21 | 5.0E-5 | NA | |
89 | hsa-miR-17-5p | CPEB4 | 2.33 | 0.30125 | -0.68 | 0.57172 | mirMAP | -0.18 | 0.00148 | NA | |
90 | hsa-miR-454-3p | CPEB4 | 1.37 | 0.14233 | -0.68 | 0.57172 | miRNATAP | -0.16 | 0.01341 | NA | |
91 | hsa-miR-17-5p | CREB3L2 | 2.33 | 0.30125 | -2.18 | 0.1571 | mirMAP | -0.14 | 0.02334 | NA | |
92 | hsa-miR-454-3p | CRISPLD1 | 1.37 | 0.14233 | -3.16 | 0.0237 | MirTarget | -0.4 | 0.01665 | NA | |
93 | hsa-miR-17-5p | CROT | 2.33 | 0.30125 | 0.76 | 0.43857 | MirTarget | -0.29 | 0 | NA | |
94 | hsa-miR-17-5p | CRY2 | 2.33 | 0.30125 | -2.56 | 0.03317 | MirTarget; TargetScan; miRNATAP | -0.14 | 6.0E-5 | NA | |
95 | hsa-miR-17-5p | CRYBG3 | 2.33 | 0.30125 | -0.03 | 0.98149 | MirTarget; TargetScan; miRNATAP | -0.24 | 0.00055 | NA | |
96 | hsa-miR-17-5p | CSF1 | 2.33 | 0.30125 | -0.95 | 0.36961 | TargetScan; miRNATAP | -0.15 | 0.04971 | NA | |
97 | hsa-miR-454-3p | CSF1 | 1.37 | 0.14233 | -0.95 | 0.36961 | MirTarget; miRNATAP | -0.2 | 0.02018 | NA | |
98 | hsa-miR-17-5p | CTSK | 2.33 | 0.30125 | -3.24 | 0.01457 | MirTarget | -0.57 | 0 | NA | |
99 | hsa-miR-454-3p | CTSK | 1.37 | 0.14233 | -3.24 | 0.01457 | MirTarget | -0.47 | 0 | NA | |
100 | hsa-miR-17-5p | CXCL14 | 2.33 | 0.30125 | 2.15 | 0.29887 | TargetScan | -0.63 | 0.00031 | NA | |
101 | hsa-miR-17-5p | CXorf23 | 2.33 | 0.30125 | -0.34 | 0.66995 | mirMAP | -0.11 | 0.00156 | NA | |
102 | hsa-miR-17-5p | CXorf36 | 2.33 | 0.30125 | -4.78 | 0 | mirMAP | -0.35 | 0 | NA | |
103 | hsa-miR-17-5p | CYBRD1 | 2.33 | 0.30125 | -3.37 | 0.0305 | MirTarget; TargetScan | -0.16 | 0.02987 | NA | |
104 | hsa-miR-454-3p | CYLD | 1.37 | 0.14233 | 0.07 | 0.95683 | miRNATAP | -0.12 | 0.0045 | 25824771 | MiR 454 prompts cell proliferation of human colorectal cancer cells by repressing CYLD expression; Bioinformatics analysis further revealed cylindromatosis CYLD a putative tumor suppressor as a potential target of miR-454; Data from luciferase reporter assays showed that miR-454 directly binds to the 3'-untranslated region 3'-UTR of CYLD mRNA and repressed expression at both transcriptional and translational levels; In sum our data provide compelling evidence that miR-454 functions as an onco-miRNA playing a crucial role in the promoting cell proliferation in CRC and its oncogenic effect is mediated chiefly through direct suppression of CYLD expression |
105 | hsa-miR-17-5p | CYP2U1 | 2.33 | 0.30125 | -2.36 | 0.00403 | MirTarget; TargetScan | -0.18 | 0.00404 | NA | |
106 | hsa-miR-454-3p | CYP4F3 | 1.37 | 0.14233 | 5.51 | 0.00095 | mirMAP | -0.39 | 0.04343 | NA | |
107 | hsa-miR-454-3p | DAAM1 | 1.37 | 0.14233 | 0.41 | 0.70774 | MirTarget; miRNATAP | -0.24 | 0.00186 | NA | |
108 | hsa-miR-17-5p | DAB2 | 2.33 | 0.30125 | -2.26 | 0.05568 | MirTarget; TargetScan; miRNATAP | -0.27 | 7.0E-5 | NA | |
109 | hsa-miR-17-5p | DIP2C | 2.33 | 0.30125 | -1.77 | 0.13518 | TargetScan | -0.13 | 0.00918 | NA | |
110 | hsa-miR-17-5p | DIXDC1 | 2.33 | 0.30125 | -4.41 | 1.0E-5 | mirMAP | -0.16 | 0.02341 | NA | |
111 | hsa-miR-454-3p | DLC1 | 1.37 | 0.14233 | -3.78 | 0.00054 | miRNATAP | -0.3 | 0.00062 | NA | |
112 | hsa-miR-17-5p | DLG2 | 2.33 | 0.30125 | -5.01 | 0.00037 | mirMAP | -0.55 | 8.0E-5 | NA | |
113 | hsa-miR-17-5p | DNAJB9 | 2.33 | 0.30125 | -1.01 | 0.40421 | TargetScan; miRNATAP | -0.14 | 0.00022 | NA | |
114 | hsa-miR-17-5p | DNAJC27 | 2.33 | 0.30125 | -1.45 | 0.03033 | miRNAWalker2 validate; miRTarBase; MirTarget; TargetScan; miRNATAP | -0.12 | 0.00024 | NA | |
115 | hsa-miR-454-3p | DNM3 | 1.37 | 0.14233 | -2.67 | 0.00065 | mirMAP | -0.27 | 0.00193 | NA | |
116 | hsa-miR-17-5p | DNMBP | 2.33 | 0.30125 | -0.36 | 0.79984 | miRNAWalker2 validate | -0.12 | 0.01184 | NA | |
117 | hsa-miR-17-5p | DOK6 | 2.33 | 0.30125 | -3.39 | 0.00047 | TargetScan | -0.42 | 0 | NA | |
118 | hsa-miR-17-5p | DPYD | 2.33 | 0.30125 | -0.1 | 0.93539 | MirTarget | -0.29 | 0.00043 | NA | |
119 | hsa-miR-17-5p | DYRK2 | 2.33 | 0.30125 | -0.04 | 0.97485 | TargetScan | -0.11 | 0.0068 | NA | |
120 | hsa-miR-454-3p | DYRK2 | 1.37 | 0.14233 | -0.04 | 0.97485 | mirMAP | -0.11 | 0.02274 | NA | |
121 | hsa-miR-17-5p | EDA2R | 2.33 | 0.30125 | -4.24 | 0.00028 | MirTarget; TargetScan | -0.38 | 0.00065 | NA | |
122 | hsa-miR-17-5p | EEA1 | 2.33 | 0.30125 | -0.13 | 0.91328 | MirTarget; TargetScan; miRNATAP | -0.15 | 0.00185 | NA | |
123 | hsa-miR-454-3p | EEA1 | 1.37 | 0.14233 | -0.13 | 0.91328 | mirMAP | -0.23 | 2.0E-5 | NA | |
124 | hsa-miR-17-5p | EGR2 | 2.33 | 0.30125 | -1.31 | 0.18551 | MirTarget; TargetScan; miRNATAP | -0.17 | 0.04204 | 27725906 | Early Growth Response 2 EGR2 protein or mRNA levels were downregulated or upregulated after overexpression or knockdown of miR-17-5p respectively; By using dual luciferase assay and Western blot we identified EGR2 as a functional target of miR-17-5p |
125 | hsa-miR-17-5p | ELK3 | 2.33 | 0.30125 | -0.61 | 0.55433 | MirTarget; TargetScan; miRNATAP | -0.22 | 0.00476 | NA | |
126 | hsa-miR-454-3p | ELK3 | 1.37 | 0.14233 | -0.61 | 0.55433 | MirTarget; miRNATAP | -0.42 | 0 | NA | |
127 | hsa-miR-409-3p | EMP2 | 0.28 | 0.79947 | 0.97 | 0.61201 | mirMAP | -0.11 | 0.01499 | NA | |
128 | hsa-miR-454-3p | ENAH | 1.37 | 0.14233 | -0.2 | 0.90546 | miRNATAP | -0.13 | 0.03879 | NA | |
129 | hsa-miR-454-3p | ENDOD1 | 1.37 | 0.14233 | -1.1 | 0.42656 | MirTarget | -0.23 | 4.0E-5 | NA | |
130 | hsa-miR-17-5p | ENPP1 | 2.33 | 0.30125 | -5.64 | 1.0E-5 | mirMAP | -0.33 | 0.00664 | NA | |
131 | hsa-miR-17-5p | ENTPD1 | 2.33 | 0.30125 | -1.63 | 0.20648 | mirMAP | -0.14 | 4.0E-5 | NA | |
132 | hsa-miR-17-5p | EPHA4 | 2.33 | 0.30125 | -1 | 0.38187 | TargetScan; miRNATAP | -0.22 | 0.0435 | NA | |
133 | hsa-miR-17-5p | EPM2AIP1 | 2.33 | 0.30125 | -1.07 | 0.40187 | mirMAP | -0.12 | 0.01401 | NA | |
134 | hsa-miR-17-5p | ESR1 | 2.33 | 0.30125 | -5.06 | 0.0022 | TargetScan | -0.71 | 0 | NA | |
135 | hsa-miR-454-3p | ESR1 | 1.37 | 0.14233 | -5.06 | 0.0022 | miRNATAP | -0.52 | 0.00045 | NA | |
136 | hsa-miR-17-5p | ETV1 | 2.33 | 0.30125 | -1.67 | 0.14511 | MirTarget; TargetScan; miRNATAP | -0.47 | 0 | 26158900 | miR 17 regulates melanoma cell motility by inhibiting the translation of ETV1; TargetScan algorithm predicts the PEA3-subfamily member ETV1 as a direct target of miR-17; Indeed a 3-4-fold decrease of ETV1 protein levels are observed following miR-17 transfection into the various melanoma lines with no significant change in ETV1 mRNA expression; Dual luciferase experiments demonstrate direct binding of miR-17 to the 3'-untranslated region of ETV1 confirmed by abolishing point mutations in the putative binding site; These combined results suggest regulation of ETV1 by miR-17 by a direct translational repression; In conclusion we show a new role for miR-17 in melanoma facilitating cell motility by targeting the translation of ETV1 protein which may support the development of metastasis |
137 | hsa-miR-454-3p | EVI5 | 1.37 | 0.14233 | -1.03 | 0.33581 | mirMAP | -0.1 | 0.00889 | NA | |
138 | hsa-miR-17-5p | EZH1 | 2.33 | 0.30125 | -1.83 | 0.14012 | MirTarget; TargetScan; miRNATAP | -0.11 | 0.00026 | 27633093 | The luciferase assay of 3'-untranslated region UTR demonstrates that EZH1 is a direct target of miR-17-5p and EZH1 RNAi recapitulates the effect of miR-17-5p overexpression on erlotinib resistance; Our results indicate that miR-17-5p down-regulation contributes to erlotinib resistance of NSCLC by modulating its target genes such as EZH1 and plasma miR-17-5p might be a potential biomarker of erlotinib response in NSCLC patients |
139 | hsa-miR-17-5p | FAIM2 | 2.33 | 0.30125 | -4.54 | 0.00017 | TargetScan | -0.55 | 2.0E-5 | NA | |
140 | hsa-miR-17-5p | FAM102A | 2.33 | 0.30125 | -0.05 | 0.97337 | TargetScan; miRNATAP | -0.21 | 1.0E-5 | NA | |
141 | hsa-miR-17-5p | FAM129A | 2.33 | 0.30125 | -0.94 | 0.49779 | TargetScan | -0.41 | 0 | 26317551 | The expression of two selected microRNAs miR-17-5p miR-106b and the expression of C1orf24 were tested in 48 benign and malignant thyroid lesions and in five thyroid carcinoma cell lines |
142 | hsa-miR-17-5p | FAM131B | 2.33 | 0.30125 | -2.46 | 0.00246 | TargetScan | -0.38 | 0 | NA | |
143 | hsa-miR-17-5p | FAM13A | 2.33 | 0.30125 | -1.61 | 0.23732 | TargetScan | -0.14 | 0.0459 | NA | |
144 | hsa-miR-454-3p | FAM155A | 1.37 | 0.14233 | -3.26 | 0.00375 | MirTarget | -0.36 | 0.00573 | NA | |
145 | hsa-miR-17-5p | FAM160B2 | 2.33 | 0.30125 | 0.09 | 0.95062 | TargetScan | -0.1 | 0.00481 | NA | |
146 | hsa-miR-454-3p | FAM179B | 1.37 | 0.14233 | -0.55 | 0.56378 | miRNATAP | -0.12 | 0.0124 | NA | |
147 | hsa-miR-17-5p | FAM189A1 | 2.33 | 0.30125 | -1.97 | 0.19359 | MirTarget; TargetScan; miRNATAP | -0.34 | 0.03934 | NA | |
148 | hsa-miR-17-5p | FAM3C | 2.33 | 0.30125 | -0.71 | 0.64888 | TargetScan | -0.14 | 0.00193 | NA | |
149 | hsa-miR-454-3p | FAM46B | 1.37 | 0.14233 | 0.7 | 0.57694 | MirTarget; miRNATAP | -0.29 | 0.01569 | NA | |
150 | hsa-miR-17-5p | FAM46C | 2.33 | 0.30125 | -0.89 | 0.48739 | MirTarget; TargetScan; miRNATAP | -0.23 | 0.00674 | NA |
Num | GO | Overlap | Size | P Value | Adj. P Value |
---|---|---|---|---|---|
1 | TISSUE DEVELOPMENT | 96 | 1518 | 2.57e-15 | 1.196e-11 |
2 | REGULATION OF CELL DIFFERENTIATION | 93 | 1492 | 1.837e-14 | 4.275e-11 |
3 | CARDIOVASCULAR SYSTEM DEVELOPMENT | 62 | 788 | 3.751e-14 | 4.364e-11 |
4 | CIRCULATORY SYSTEM DEVELOPMENT | 62 | 788 | 3.751e-14 | 4.364e-11 |
5 | POSITIVE REGULATION OF BIOSYNTHETIC PROCESS | 102 | 1805 | 4.007e-13 | 3.729e-10 |
6 | POSITIVE REGULATION OF GENE EXPRESSION | 98 | 1733 | 1.237e-12 | 9.59e-10 |
7 | REGULATION OF INTRACELLULAR SIGNAL TRANSDUCTION | 94 | 1656 | 3.181e-12 | 2.115e-09 |
8 | ORGAN MORPHOGENESIS | 60 | 841 | 6.472e-12 | 3.764e-09 |
9 | MUSCLE TISSUE DEVELOPMENT | 31 | 275 | 1.933e-11 | 9.994e-09 |
10 | REGULATION OF SMALL GTPASE MEDIATED SIGNAL TRANSDUCTION | 31 | 278 | 2.56e-11 | 1.191e-08 |
11 | REGULATION OF TRANSCRIPTION FROM RNA POLYMERASE II PROMOTER | 96 | 1784 | 3.685e-11 | 1.559e-08 |
12 | TISSUE MORPHOGENESIS | 44 | 533 | 5.108e-11 | 1.981e-08 |
13 | REGULATION OF MULTICELLULAR ORGANISMAL DEVELOPMENT | 91 | 1672 | 7.312e-11 | 2.617e-08 |
14 | POSITIVE REGULATION OF CELL MORPHOGENESIS INVOLVED IN DIFFERENTIATION | 23 | 162 | 7.922e-11 | 2.633e-08 |
15 | POSITIVE REGULATION OF MOLECULAR FUNCTION | 95 | 1791 | 1.045e-10 | 3.241e-08 |
16 | POSITIVE REGULATION OF CELL COMMUNICATION | 85 | 1532 | 1.341e-10 | 3.325e-08 |
17 | EMBRYONIC ORGAN MORPHOGENESIS | 30 | 279 | 1.33e-10 | 3.325e-08 |
18 | HEART DEVELOPMENT | 40 | 466 | 1.246e-10 | 3.325e-08 |
19 | NEUROGENESIS | 80 | 1402 | 1.358e-10 | 3.325e-08 |
20 | REGULATION OF RAS PROTEIN SIGNAL TRANSDUCTION | 24 | 184 | 1.862e-10 | 4.333e-08 |
21 | SKELETAL SYSTEM DEVELOPMENT | 39 | 455 | 2.234e-10 | 4.95e-08 |
22 | POSITIVE REGULATION OF RESPONSE TO STIMULUS | 99 | 1929 | 2.42e-10 | 5.109e-08 |
23 | CELLULAR RESPONSE TO ORGANIC SUBSTANCE | 96 | 1848 | 2.525e-10 | 5.109e-08 |
24 | CELL DEVELOPMENT | 80 | 1426 | 3.05e-10 | 5.913e-08 |
25 | POSITIVE REGULATION OF CATALYTIC ACTIVITY | 83 | 1518 | 4.673e-10 | 8.363e-08 |
26 | REGULATION OF CELLULAR COMPONENT MOVEMENT | 53 | 771 | 4.624e-10 | 8.363e-08 |
27 | VASCULATURE DEVELOPMENT | 39 | 469 | 5.399e-10 | 9.304e-08 |
28 | EMBRYO DEVELOPMENT | 58 | 894 | 6.025e-10 | 9.667e-08 |
29 | POSITIVE REGULATION OF CELL DIFFERENTIATION | 55 | 823 | 5.968e-10 | 9.667e-08 |
30 | EMBRYONIC MORPHOGENESIS | 42 | 539 | 8.373e-10 | 1.299e-07 |
31 | TUBE MORPHOGENESIS | 31 | 323 | 1.111e-09 | 1.668e-07 |
32 | EMBRYONIC ORGAN DEVELOPMENT | 35 | 406 | 1.659e-09 | 2.412e-07 |
33 | TUBE DEVELOPMENT | 42 | 552 | 1.711e-09 | 2.413e-07 |
34 | REGULATION OF ANATOMICAL STRUCTURE MORPHOGENESIS | 62 | 1021 | 1.983e-09 | 2.714e-07 |
35 | MUSCLE STRUCTURE DEVELOPMENT | 36 | 432 | 2.401e-09 | 3.192e-07 |
36 | POSITIVE REGULATION OF TRANSCRIPTION FROM RNA POLYMERASE II PROMOTER | 61 | 1004 | 2.657e-09 | 3.435e-07 |
37 | REGULATION OF GTPASE ACTIVITY | 47 | 673 | 2.875e-09 | 3.616e-07 |
38 | REGULATION OF SYSTEM PROCESS | 39 | 507 | 4.923e-09 | 5.873e-07 |
39 | NEGATIVE REGULATION OF DEVELOPMENTAL PROCESS | 52 | 801 | 4.877e-09 | 5.873e-07 |
40 | POSITIVE REGULATION OF CELL DEVELOPMENT | 37 | 472 | 7.481e-09 | 8.702e-07 |
41 | CELLULAR RESPONSE TO ENDOGENOUS STIMULUS | 60 | 1008 | 7.762e-09 | 8.809e-07 |
42 | POSITIVE REGULATION OF DEVELOPMENTAL PROCESS | 65 | 1142 | 1e-08 | 1.108e-06 |
43 | CENTRAL NERVOUS SYSTEM DEVELOPMENT | 54 | 872 | 1.231e-08 | 1.332e-06 |
44 | POSITIVE REGULATION OF LOCOMOTION | 34 | 420 | 1.394e-08 | 1.474e-06 |
45 | MORPHOGENESIS OF AN EPITHELIUM | 33 | 400 | 1.444e-08 | 1.493e-06 |
46 | RESPONSE TO ENDOGENOUS STIMULUS | 76 | 1450 | 1.754e-08 | 1.775e-06 |
47 | ANATOMICAL STRUCTURE FORMATION INVOLVED IN MORPHOGENESIS | 57 | 957 | 1.859e-08 | 1.84e-06 |
48 | BLOOD VESSEL MORPHOGENESIS | 31 | 364 | 1.915e-08 | 1.856e-06 |
49 | REGULATION OF CELL DEVELOPMENT | 52 | 836 | 2.022e-08 | 1.92e-06 |
50 | EPITHELIUM DEVELOPMENT | 56 | 945 | 2.978e-08 | 2.771e-06 |
51 | NEGATIVE REGULATION OF GENE EXPRESSION | 76 | 1493 | 5.923e-08 | 5.404e-06 |
52 | NEURON DIFFERENTIATION | 52 | 874 | 8.476e-08 | 7.441e-06 |
53 | NEGATIVE REGULATION OF CELL DIFFERENTIATION | 41 | 609 | 8.415e-08 | 7.441e-06 |
54 | REGULATION OF PHOSPHORUS METABOLIC PROCESS | 80 | 1618 | 8.695e-08 | 7.492e-06 |
55 | POSITIVE REGULATION OF INTRACELLULAR SIGNAL TRANSDUCTION | 52 | 876 | 9.112e-08 | 7.709e-06 |
56 | BIOLOGICAL ADHESION | 58 | 1032 | 1.035e-07 | 8.601e-06 |
57 | REGULATION OF PROTEIN MODIFICATION PROCESS | 83 | 1710 | 1.063e-07 | 8.674e-06 |
58 | REGULATION OF HYDROLASE ACTIVITY | 69 | 1327 | 1.179e-07 | 9.457e-06 |
59 | NEGATIVE REGULATION OF CELL PROLIFERATION | 42 | 643 | 1.337e-07 | 1.055e-05 |
60 | NEGATIVE REGULATION OF RESPONSE TO STIMULUS | 70 | 1360 | 1.392e-07 | 1.08e-05 |
61 | POSITIVE REGULATION OF CELL DEATH | 40 | 605 | 1.958e-07 | 1.494e-05 |
62 | INTRACELLULAR SIGNAL TRANSDUCTION | 77 | 1572 | 2.299e-07 | 1.726e-05 |
63 | POSITIVE REGULATION OF HYDROLASE ACTIVITY | 52 | 905 | 2.523e-07 | 1.863e-05 |
64 | NEGATIVE REGULATION OF MULTICELLULAR ORGANISMAL PROCESS | 55 | 983 | 2.621e-07 | 1.905e-05 |
65 | POSITIVE REGULATION OF MULTICELLULAR ORGANISMAL PROCESS | 70 | 1395 | 3.618e-07 | 2.551e-05 |
66 | NEGATIVE REGULATION OF TRANSCRIPTION FROM RNA POLYMERASE II PROMOTER | 45 | 740 | 3.601e-07 | 2.551e-05 |
67 | REGULATION OF CELL MORPHOGENESIS INVOLVED IN DIFFERENTIATION | 27 | 337 | 5.38e-07 | 3.737e-05 |
68 | CELL MORPHOGENESIS INVOLVED IN DIFFERENTIATION | 35 | 513 | 5.594e-07 | 3.828e-05 |
69 | SENSORY ORGAN DEVELOPMENT | 34 | 493 | 6.368e-07 | 4.295e-05 |
70 | REGULATION OF MAPK CASCADE | 41 | 660 | 7.047e-07 | 4.684e-05 |
71 | ENZYME LINKED RECEPTOR PROTEIN SIGNALING PATHWAY | 42 | 689 | 8.421e-07 | 5.519e-05 |
72 | REGULATION OF TRANSMEMBRANE RECEPTOR PROTEIN SERINE THREONINE KINASE SIGNALING PATHWAY | 20 | 207 | 9.196e-07 | 5.943e-05 |
73 | POSITIVE REGULATION OF NEURON DIFFERENTIATION | 25 | 306 | 9.905e-07 | 6.314e-05 |
74 | BONE DEVELOPMENT | 17 | 156 | 1.144e-06 | 7.194e-05 |
75 | NEGATIVE REGULATION OF CELL COMMUNICATION | 61 | 1192 | 1.166e-06 | 7.234e-05 |
76 | EMBRYO DEVELOPMENT ENDING IN BIRTH OR EGG HATCHING | 36 | 554 | 1.216e-06 | 7.442e-05 |
77 | CARDIAC MUSCLE TISSUE DEVELOPMENT | 16 | 140 | 1.248e-06 | 7.542e-05 |
78 | LOCOMOTION | 58 | 1114 | 1.271e-06 | 7.581e-05 |
79 | POSITIVE REGULATION OF PHOSPHATE METABOLIC PROCESS | 55 | 1036 | 1.354e-06 | 7.874e-05 |
80 | POSITIVE REGULATION OF PHOSPHORUS METABOLIC PROCESS | 55 | 1036 | 1.354e-06 | 7.874e-05 |
81 | REGULATION OF CELL ADHESION | 39 | 629 | 1.389e-06 | 7.978e-05 |
82 | REGULATION OF MUSCLE SYSTEM PROCESS | 19 | 195 | 1.513e-06 | 8.585e-05 |
83 | CELL CELL ADHESION | 38 | 608 | 1.572e-06 | 8.706e-05 |
84 | ANGIOGENESIS | 24 | 293 | 1.556e-06 | 8.706e-05 |
85 | REGULATION OF OSSIFICATION | 18 | 178 | 1.667e-06 | 9.124e-05 |
86 | NEGATIVE REGULATION OF NITROGEN COMPOUND METABOLIC PROCESS | 72 | 1517 | 1.9e-06 | 0.0001028 |
87 | EAR MORPHOGENESIS | 14 | 112 | 1.965e-06 | 0.0001039 |
88 | REGULATION OF CHEMOTAXIS | 18 | 180 | 1.959e-06 | 0.0001039 |
89 | RHYTHMIC PROCESS | 24 | 298 | 2.096e-06 | 0.0001096 |
90 | NEURON PROJECTION DEVELOPMENT | 35 | 545 | 2.234e-06 | 0.0001142 |
91 | POSITIVE REGULATION OF AXONOGENESIS | 11 | 69 | 2.221e-06 | 0.0001142 |
92 | SKELETAL SYSTEM MORPHOGENESIS | 19 | 201 | 2.382e-06 | 0.0001205 |
93 | MOVEMENT OF CELL OR SUBCELLULAR COMPONENT | 63 | 1275 | 2.462e-06 | 0.0001232 |
94 | REGULATION OF CELL MORPHOGENESIS | 35 | 552 | 2.971e-06 | 0.0001471 |
95 | REGULATION OF NEURON DIFFERENTIATION | 35 | 554 | 3.22e-06 | 0.0001577 |
96 | POSITIVE REGULATION OF STRESS ACTIVATED PROTEIN KINASE SIGNALING CASCADE | 15 | 135 | 3.81e-06 | 0.0001847 |
97 | HOMOPHILIC CELL ADHESION VIA PLASMA MEMBRANE ADHESION MOLECULES | 16 | 153 | 4.049e-06 | 0.0001942 |
98 | HEAD DEVELOPMENT | 41 | 709 | 4.239e-06 | 0.0001993 |
99 | TRANSMEMBRANE RECEPTOR PROTEIN SERINE THREONINE KINASE SIGNALING PATHWAY | 18 | 190 | 4.24e-06 | 0.0001993 |
100 | RESPONSE TO MECHANICAL STIMULUS | 19 | 210 | 4.549e-06 | 0.0002096 |
101 | DEVELOPMENTAL GROWTH | 25 | 333 | 4.532e-06 | 0.0002096 |
102 | NEURON DEVELOPMENT | 40 | 687 | 4.728e-06 | 0.0002134 |
103 | REGULATION OF CELL SUBSTRATE ADHESION | 17 | 173 | 4.771e-06 | 0.0002134 |
104 | POSITIVE REGULATION OF PROTEIN MODIFICATION PROCESS | 57 | 1135 | 4.759e-06 | 0.0002134 |
105 | POSITIVE REGULATION OF MAPK CASCADE | 31 | 470 | 4.986e-06 | 0.0002209 |
106 | NEURON PROJECTION MORPHOGENESIS | 28 | 402 | 5.186e-06 | 0.0002276 |
107 | CELLULAR RESPONSE TO OXYGEN CONTAINING COMPOUND | 44 | 799 | 6.557e-06 | 0.0002851 |
108 | REGULATION OF JNK CASCADE | 16 | 159 | 6.666e-06 | 0.0002872 |
109 | INNER EAR MORPHOGENESIS | 12 | 92 | 6.766e-06 | 0.0002888 |
110 | REGULATION OF STRESS ACTIVATED PROTEIN KINASE SIGNALING CASCADE | 18 | 197 | 7.044e-06 | 0.0002979 |
111 | MUSCLE CELL DIFFERENTIATION | 20 | 237 | 7.372e-06 | 0.000309 |
112 | REGULATION OF RHO PROTEIN SIGNAL TRANSDUCTION | 13 | 109 | 7.698e-06 | 0.0003198 |
113 | POSITIVE REGULATION OF SMALL GTPASE MEDIATED SIGNAL TRANSDUCTION | 8 | 39 | 7.888e-06 | 0.0003248 |
114 | REGULATION OF CELL PROLIFERATION | 69 | 1496 | 8.409e-06 | 0.0003432 |
115 | MESODERM MORPHOGENESIS | 10 | 66 | 1.028e-05 | 0.0004159 |
116 | CARTILAGE DEVELOPMENT | 15 | 147 | 1.088e-05 | 0.0004364 |
117 | CELL CELL ADHESION VIA PLASMA MEMBRANE ADHESION MOLECULES | 18 | 204 | 1.141e-05 | 0.000454 |
118 | CELLULAR COMPONENT MORPHOGENESIS | 47 | 900 | 1.266e-05 | 0.0004994 |
119 | ACTIN FILAMENT BASED PROCESS | 29 | 450 | 1.555e-05 | 0.0006081 |
120 | REGULATION OF CELLULAR RESPONSE TO GROWTH FACTOR STIMULUS | 19 | 229 | 1.578e-05 | 0.000612 |
121 | REGULATION OF NERVOUS SYSTEM DEVELOPMENT | 41 | 750 | 1.618e-05 | 0.0006122 |
122 | TRANSCRIPTION FROM RNA POLYMERASE II PROMOTER | 40 | 724 | 1.615e-05 | 0.0006122 |
123 | RESPONSE TO OXYGEN CONTAINING COMPOUND | 64 | 1381 | 1.592e-05 | 0.0006122 |
124 | MESENCHYME DEVELOPMENT | 17 | 190 | 1.659e-05 | 0.0006226 |
125 | REGULATION OF CELL DEATH | 67 | 1472 | 1.76e-05 | 0.0006551 |
126 | MESODERM DEVELOPMENT | 13 | 118 | 1.837e-05 | 0.0006782 |
127 | CELL MOTILITY | 44 | 835 | 1.945e-05 | 0.0007014 |
128 | HEART MORPHOGENESIS | 18 | 212 | 1.927e-05 | 0.0007014 |
129 | LOCALIZATION OF CELL | 44 | 835 | 1.945e-05 | 0.0007014 |
130 | GROWTH | 27 | 410 | 2.084e-05 | 0.000746 |
131 | CELL DEATH | 50 | 1001 | 2.172e-05 | 0.0007684 |
132 | POSITIVE REGULATION OF EPITHELIAL CELL MIGRATION | 12 | 103 | 2.18e-05 | 0.0007684 |
133 | TISSUE REMODELING | 11 | 87 | 2.202e-05 | 0.0007703 |
134 | CIRCULATORY SYSTEM PROCESS | 25 | 366 | 2.292e-05 | 0.0007909 |
135 | UROGENITAL SYSTEM DEVELOPMENT | 22 | 299 | 2.295e-05 | 0.0007909 |
136 | EAR DEVELOPMENT | 17 | 195 | 2.324e-05 | 0.0007953 |
137 | POSITIVE REGULATION OF NERVOUS SYSTEM DEVELOPMENT | 28 | 437 | 2.414e-05 | 0.0008197 |
138 | CELL MORPHOGENESIS INVOLVED IN NEURON DIFFERENTIATION | 25 | 368 | 2.509e-05 | 0.0008461 |
139 | EMBRYONIC SKELETAL SYSTEM DEVELOPMENT | 13 | 122 | 2.629e-05 | 0.00088 |
140 | POSITIVE REGULATION OF EPITHELIAL TO MESENCHYMAL TRANSITION | 7 | 34 | 2.873e-05 | 0.000926 |
141 | CARDIAC MUSCLE CELL DIFFERENTIATION | 10 | 74 | 2.886e-05 | 0.000926 |
142 | MULTICELLULAR ORGANISMAL SIGNALING | 13 | 123 | 2.869e-05 | 0.000926 |
143 | SENSORY ORGAN MORPHOGENESIS | 19 | 239 | 2.865e-05 | 0.000926 |
144 | EMBRYONIC CRANIAL SKELETON MORPHOGENESIS | 8 | 46 | 2.834e-05 | 0.000926 |
145 | POSITIVE REGULATION OF CELL PROJECTION ORGANIZATION | 22 | 303 | 2.811e-05 | 0.000926 |
146 | REGULATION OF FAT CELL DIFFERENTIATION | 12 | 106 | 2.916e-05 | 0.0009293 |
147 | REGULATION OF SMOOTH MUSCLE CONTRACTION | 9 | 60 | 3.096e-05 | 0.0009799 |
148 | OLFACTORY BULB INTERNEURON DIFFERENTIATION | 5 | 15 | 3.38e-05 | 0.001063 |
149 | FORMATION OF PRIMARY GERM LAYER | 12 | 110 | 4.227e-05 | 0.00132 |
150 | OLFACTORY LOBE DEVELOPMENT | 7 | 36 | 4.254e-05 | 0.00132 |
151 | CELL JUNCTION ORGANIZATION | 16 | 185 | 4.425e-05 | 0.001364 |
152 | REGULATION OF EPITHELIAL CELL MIGRATION | 15 | 166 | 4.6e-05 | 0.001391 |
153 | REGULATION OF MUSCLE CONTRACTION | 14 | 147 | 4.604e-05 | 0.001391 |
154 | RESPONSE TO HORMONE | 45 | 893 | 4.605e-05 | 0.001391 |
155 | POSITIVE REGULATION OF PROTEIN METABOLIC PROCESS | 66 | 1492 | 4.907e-05 | 0.001473 |
156 | TELENCEPHALON DEVELOPMENT | 18 | 228 | 5.062e-05 | 0.00151 |
157 | CARDIOCYTE DIFFERENTIATION | 11 | 96 | 5.574e-05 | 0.001652 |
158 | REGULATION OF CELL PROJECTION ORGANIZATION | 32 | 558 | 5.684e-05 | 0.001674 |
159 | RESPONSE TO CYTOKINE | 38 | 714 | 5.868e-05 | 0.001717 |
160 | REGULATION OF MAP KINASE ACTIVITY | 22 | 319 | 6.089e-05 | 0.001763 |
161 | STEM CELL DIFFERENTIATION | 16 | 190 | 6.102e-05 | 0.001763 |
162 | POSITIVE REGULATION OF NEURON PROJECTION DEVELOPMENT | 18 | 232 | 6.346e-05 | 0.001823 |
163 | REGULATION OF MUSCLE CELL DIFFERENTIATION | 14 | 152 | 6.647e-05 | 0.001897 |
164 | TRANSCRIPTION INITIATION FROM RNA POLYMERASE II PROMOTER | 14 | 153 | 7.139e-05 | 0.002025 |
165 | REGULATION OF TRANSFORMING GROWTH FACTOR BETA RECEPTOR SIGNALING PATHWAY | 11 | 99 | 7.408e-05 | 0.002064 |
166 | REGULATION OF CELLULAR RESPONSE TO TRANSFORMING GROWTH FACTOR BETA STIMULUS | 11 | 99 | 7.408e-05 | 0.002064 |
167 | DEVELOPMENTAL MATURATION | 16 | 193 | 7.356e-05 | 0.002064 |
168 | CONNECTIVE TISSUE DEVELOPMENT | 16 | 194 | 7.822e-05 | 0.002166 |
169 | NEGATIVE REGULATION OF CELL SUBSTRATE ADHESION | 8 | 53 | 8.157e-05 | 0.002246 |
170 | PROTEIN PHOSPHORYLATION | 46 | 944 | 8.415e-05 | 0.002303 |
171 | ORGAN GROWTH | 9 | 68 | 8.524e-05 | 0.00232 |
172 | RESPONSE TO EXTERNAL STIMULUS | 76 | 1821 | 8.651e-05 | 0.00234 |
173 | POSITIVE REGULATION OF OSSIFICATION | 10 | 84 | 8.717e-05 | 0.002345 |
174 | SMOOTH MUSCLE TISSUE DEVELOPMENT | 5 | 18 | 9.016e-05 | 0.002411 |
175 | POSITIVE REGULATION OF CHEMOTAXIS | 12 | 120 | 9.932e-05 | 0.002641 |
176 | REGULATION OF EPITHELIAL CELL PROLIFERATION | 20 | 285 | 0.0001028 | 0.002718 |
177 | POSITIVE REGULATION OF CELLULAR COMPONENT ORGANIZATION | 53 | 1152 | 0.0001076 | 0.002781 |
178 | POSITIVE REGULATION OF REACTIVE OXYGEN SPECIES METABOLIC PROCESS | 10 | 86 | 0.0001065 | 0.002781 |
179 | CRANIAL SKELETAL SYSTEM DEVELOPMENT | 8 | 55 | 0.0001069 | 0.002781 |
180 | CENTRAL NERVOUS SYSTEM NEURON DEVELOPMENT | 9 | 70 | 0.0001073 | 0.002781 |
181 | FOREBRAIN DEVELOPMENT | 23 | 357 | 0.0001169 | 0.002969 |
182 | REGULATION OF EPITHELIAL CELL DIFFERENTIATION | 12 | 122 | 0.0001165 | 0.002969 |
183 | CELL PROJECTION ORGANIZATION | 44 | 902 | 0.0001174 | 0.002969 |
184 | DEVELOPMENTAL GROWTH INVOLVED IN MORPHOGENESIS | 11 | 104 | 0.0001161 | 0.002969 |
185 | POSITIVE REGULATION OF KINASE ACTIVITY | 28 | 482 | 0.0001321 | 0.003308 |
186 | REGULATION OF NEURON PROJECTION DEVELOPMENT | 25 | 408 | 0.0001322 | 0.003308 |
187 | KIDNEY EPITHELIUM DEVELOPMENT | 12 | 125 | 0.000147 | 0.003657 |
188 | OLFACTORY BULB INTERNEURON DEVELOPMENT | 4 | 11 | 0.0001491 | 0.003691 |
189 | REGULATION OF KINASE ACTIVITY | 39 | 776 | 0.0001567 | 0.003798 |
190 | RELAXATION OF MUSCLE | 5 | 20 | 0.000156 | 0.003798 |
191 | ENDOTHELIUM DEVELOPMENT | 10 | 90 | 0.0001564 | 0.003798 |
192 | MESONEPHROS DEVELOPMENT | 10 | 90 | 0.0001564 | 0.003798 |
193 | TAXIS | 27 | 464 | 0.0001687 | 0.004068 |
194 | CENTRAL NERVOUS SYSTEM NEURON DIFFERENTIATION | 14 | 166 | 0.0001708 | 0.004096 |
195 | OSSIFICATION | 18 | 251 | 0.0001722 | 0.00411 |
196 | CELLULAR RESPONSE TO ORGANIC CYCLIC COMPOUND | 27 | 465 | 0.0001747 | 0.004147 |
197 | REGULATION OF BIOMINERAL TISSUE DEVELOPMENT | 9 | 75 | 0.0001839 | 0.004343 |
198 | METANEPHRIC NEPHRON DEVELOPMENT | 6 | 32 | 0.0001878 | 0.004413 |
199 | REGULATION OF AXONOGENESIS | 14 | 168 | 0.0001936 | 0.004528 |
200 | CHONDROCYTE DIFFERENTIATION | 8 | 60 | 0.0001996 | 0.004644 |
201 | MUSCLE ORGAN DEVELOPMENT | 19 | 277 | 0.000204 | 0.004699 |
202 | EMBRYONIC SKELETAL SYSTEM MORPHOGENESIS | 10 | 93 | 0.0002055 | 0.004699 |
203 | APPENDAGE DEVELOPMENT | 14 | 169 | 0.000206 | 0.004699 |
204 | LIMB DEVELOPMENT | 14 | 169 | 0.000206 | 0.004699 |
205 | NEGATIVE REGULATION OF CELL GROWTH | 14 | 170 | 0.0002191 | 0.004972 |
206 | EMBRYONIC DIGESTIVE TRACT DEVELOPMENT | 6 | 33 | 0.0002243 | 0.004998 |
207 | ACTION POTENTIAL | 10 | 94 | 0.0002245 | 0.004998 |
208 | RESPONSE TO BMP | 10 | 94 | 0.0002245 | 0.004998 |
209 | CELLULAR RESPONSE TO BMP STIMULUS | 10 | 94 | 0.0002245 | 0.004998 |
210 | REGULATION OF TRANSCRIPTION FACTOR IMPORT INTO NUCLEUS | 10 | 95 | 0.000245 | 0.005415 |
211 | NEGATIVE REGULATION OF GROWTH | 17 | 236 | 0.0002456 | 0.005415 |
212 | STRIATED MUSCLE CELL DIFFERENTIATION | 14 | 173 | 0.0002626 | 0.005764 |
213 | REGULATION OF CARTILAGE DEVELOPMENT | 8 | 63 | 0.0002815 | 0.006123 |
214 | REGULATION OF MYOBLAST DIFFERENTIATION | 7 | 48 | 0.0002837 | 0.006123 |
215 | MESENCHYMAL CELL DIFFERENTIATION | 12 | 134 | 0.0002825 | 0.006123 |
216 | CELLULAR RESPONSE TO NITROGEN COMPOUND | 28 | 505 | 0.0002842 | 0.006123 |
217 | GLAND MORPHOGENESIS | 10 | 97 | 0.0002906 | 0.006231 |
218 | HOMEOSTASIS OF NUMBER OF CELLS | 14 | 175 | 0.0002956 | 0.006309 |
219 | NEGATIVE REGULATION OF LOCOMOTION | 18 | 263 | 0.0003054 | 0.006315 |
220 | REGULATION OF RESPONSE TO STRESS | 62 | 1468 | 0.0002996 | 0.006315 |
221 | GASTRULATION | 13 | 155 | 0.0003049 | 0.006315 |
222 | CELLULAR RESPONSE TO STEROID HORMONE STIMULUS | 16 | 218 | 0.0003006 | 0.006315 |
223 | CELLULAR RESPONSE TO MECHANICAL STIMULUS | 9 | 80 | 0.0003014 | 0.006315 |
224 | CELL GROWTH | 12 | 135 | 0.0003026 | 0.006315 |
225 | CELLULAR RESPONSE TO ABIOTIC STIMULUS | 18 | 263 | 0.0003054 | 0.006315 |
226 | CELLULAR RESPONSE TO LIPID | 26 | 457 | 0.0003139 | 0.006464 |
227 | CELLULAR RESPONSE TO EXTERNAL STIMULUS | 18 | 264 | 0.0003197 | 0.006554 |
228 | REGULATION OF ORGAN MORPHOGENESIS | 17 | 242 | 0.0003294 | 0.006722 |
229 | REGULATION OF ACTIN FILAMENT BASED PROCESS | 20 | 312 | 0.0003412 | 0.006933 |
230 | CELL PROLIFERATION | 34 | 672 | 0.0003639 | 0.007363 |
231 | POSITIVE REGULATION OF STEM CELL DIFFERENTIATION | 7 | 50 | 0.0003674 | 0.007388 |
232 | POSITIVE REGULATION OF AXON EXTENSION | 6 | 36 | 0.0003684 | 0.007388 |
233 | POSITIVE REGULATION OF TRANSMEMBRANE RECEPTOR PROTEIN SERINE THREONINE KINASE SIGNALING PATHWAY | 10 | 100 | 0.0003722 | 0.007433 |
234 | NEGATIVE REGULATION OF CELL ADHESION | 16 | 223 | 0.000387 | 0.007695 |
235 | NEGATIVE REGULATION OF CHEMOTAXIS | 7 | 51 | 0.0004161 | 0.008238 |
236 | MEMBRANE DEPOLARIZATION DURING CARDIAC MUSCLE CELL ACTION POTENTIAL | 4 | 14 | 0.0004241 | 0.008361 |
237 | CELL COMMUNICATION INVOLVED IN CARDIAC CONDUCTION | 6 | 37 | 0.0004297 | 0.008366 |
238 | CARDIAC MUSCLE CELL ACTION POTENTIAL | 6 | 37 | 0.0004297 | 0.008366 |
239 | NEGATIVE REGULATION OF EPITHELIAL CELL DIFFERENTIATION | 6 | 37 | 0.0004297 | 0.008366 |
240 | NEGATIVE REGULATION OF TRANSMEMBRANE RECEPTOR PROTEIN SERINE THREONINE KINASE SIGNALING PATHWAY | 10 | 102 | 0.0004366 | 0.008464 |
241 | NEGATIVE REGULATION OF CELLULAR RESPONSE TO GROWTH FACTOR STIMULUS | 11 | 121 | 0.000441 | 0.008514 |
242 | REGULATION OF PROTEIN IMPORT | 14 | 183 | 0.0004655 | 0.00895 |
243 | EPITHELIAL CELL DIFFERENTIATION | 27 | 495 | 0.0004677 | 0.008955 |
244 | HEART PROCESS | 9 | 85 | 0.0004752 | 0.009024 |
245 | NEURON PROJECTION GUIDANCE | 15 | 205 | 0.0004745 | 0.009024 |
246 | REGULATION OF PROTEIN SERINE THREONINE KINASE ACTIVITY | 26 | 470 | 0.0004801 | 0.009081 |
247 | POSITIVE REGULATION OF BIOMINERAL TISSUE DEVELOPMENT | 6 | 38 | 0.0004988 | 0.009359 |
248 | NEGATIVE REGULATION OF RESPONSE TO EXTERNAL STIMULUS | 18 | 274 | 0.0004985 | 0.009359 |
249 | POSITIVE REGULATION OF EXTRINSIC APOPTOTIC SIGNALING PATHWAY | 7 | 53 | 0.0005288 | 0.009882 |
250 | CELLULAR RESPONSE TO HORMONE STIMULUS | 29 | 552 | 0.0005362 | 0.009979 |
Num | GO | Overlap | Size | P Value | Adj. P Value |
---|---|---|---|---|---|
1 | REGULATORY REGION NUCLEIC ACID BINDING | 54 | 818 | 1.339e-09 | 9.382e-07 |
2 | RNA POLYMERASE II TRANSCRIPTION FACTOR ACTIVITY SEQUENCE SPECIFIC DNA BINDING | 45 | 629 | 3.03e-09 | 9.382e-07 |
3 | NUCLEIC ACID BINDING TRANSCRIPTION FACTOR ACTIVITY | 69 | 1199 | 2.112e-09 | 9.382e-07 |
4 | TRANSCRIPTION FACTOR ACTIVITY RNA POLYMERASE II CORE PROMOTER PROXIMAL REGION SEQUENCE SPECIFIC BINDING | 28 | 328 | 8.933e-08 | 2.075e-05 |
5 | TRANSCRIPTION FACTOR BINDING | 35 | 524 | 9.145e-07 | 0.0001699 |
6 | DOUBLE STRANDED DNA BINDING | 44 | 764 | 2.081e-06 | 0.0003222 |
7 | E BOX BINDING | 8 | 34 | 2.621e-06 | 0.0003253 |
8 | GUANYL NUCLEOTIDE EXCHANGE FACTOR ACTIVITY | 24 | 303 | 2.801e-06 | 0.0003253 |
9 | TRANSCRIPTIONAL ACTIVATOR ACTIVITY RNA POLYMERASE II TRANSCRIPTION REGULATORY REGION SEQUENCE SPECIFIC BINDING | 24 | 315 | 5.464e-06 | 0.000564 |
10 | CORE PROMOTER PROXIMAL REGION DNA BINDING | 26 | 371 | 1.008e-05 | 0.0009362 |
11 | TRANSCRIPTIONAL ACTIVATOR ACTIVITY RNA POLYMERASE II CORE PROMOTER PROXIMAL REGION SEQUENCE SPECIFIC BINDING | 19 | 226 | 1.31e-05 | 0.001106 |
12 | MOLECULAR FUNCTION REGULATOR | 63 | 1353 | 1.614e-05 | 0.00125 |
13 | RECEPTOR SIGNALING PROTEIN ACTIVITY | 16 | 172 | 1.806e-05 | 0.00129 |
14 | KINASE ACTIVITY | 44 | 842 | 2.378e-05 | 0.001489 |
15 | RNA POLYMERASE II TRANSCRIPTION FACTOR BINDING | 12 | 104 | 2.405e-05 | 0.001489 |
16 | TRANSCRIPTION FACTOR ACTIVITY PROTEIN BINDING | 34 | 588 | 2.833e-05 | 0.001645 |
17 | RECEPTOR SIGNALING PROTEIN SERINE THREONINE KINASE ACTIVITY | 11 | 92 | 3.743e-05 | 0.002046 |
18 | RHO GUANYL NUCLEOTIDE EXCHANGE FACTOR ACTIVITY | 10 | 77 | 4.099e-05 | 0.002116 |
19 | TRANSFORMING GROWTH FACTOR BETA BINDING | 5 | 16 | 4.807e-05 | 0.00235 |
20 | CALCIUM ION BINDING | 37 | 697 | 7.734e-05 | 0.003592 |
21 | BHLH TRANSCRIPTION FACTOR BINDING | 6 | 28 | 8.556e-05 | 0.003785 |
22 | PROTEIN DIMERIZATION ACTIVITY | 53 | 1149 | 0.0001007 | 0.004252 |
23 | SMAD BINDING | 9 | 72 | 0.0001338 | 0.005356 |
24 | ACTIVATING TRANSCRIPTION FACTOR BINDING | 8 | 57 | 0.0001384 | 0.005356 |
25 | PROTEIN KINASE ACTIVITY | 34 | 640 | 0.0001482 | 0.005508 |
26 | RAS GUANYL NUCLEOTIDE EXCHANGE FACTOR ACTIVITY | 17 | 228 | 0.000163 | 0.005824 |
27 | STEROID HORMONE RECEPTOR ACTIVITY | 8 | 59 | 0.0001771 | 0.006095 |
28 | CYTOKINE BINDING | 10 | 92 | 0.0001878 | 0.006232 |
29 | SEQUENCE SPECIFIC DNA BINDING | 48 | 1037 | 0.0001992 | 0.006383 |
30 | TRANSFERASE ACTIVITY TRANSFERRING PHOSPHORUS CONTAINING GROUPS | 46 | 992 | 0.0002601 | 0.008056 |
31 | TRANSCRIPTION FACTOR ACTIVITY DIRECT LIGAND REGULATED SEQUENCE SPECIFIC DNA BINDING | 7 | 48 | 0.0002837 | 0.008236 |
32 | ENZYME BINDING | 71 | 1737 | 0.0002793 | 0.008236 |
33 | PROTEIN HOMODIMERIZATION ACTIVITY | 36 | 722 | 0.0003242 | 0.009128 |
Num | GO | Overlap | Size | P Value | Adj. P Value |
---|---|---|---|---|---|
1 | CELL JUNCTION | 60 | 1151 | 7.884e-07 | 0.0002302 |
2 | ANCHORING JUNCTION | 34 | 489 | 5.287e-07 | 0.0002302 |
3 | CELL SUBSTRATE JUNCTION | 29 | 398 | 1.441e-06 | 0.0002806 |
4 | INTRINSIC COMPONENT OF PLASMA MEMBRANE | 75 | 1649 | 5.36e-06 | 0.0007826 |
5 | CELL CELL CONTACT ZONE | 10 | 64 | 7.745e-06 | 0.0009046 |
6 | MEMBRANE MICRODOMAIN | 22 | 288 | 1.284e-05 | 0.001249 |
7 | T TUBULE | 8 | 45 | 2.397e-05 | 0.002 |
8 | MEMBRANE REGION | 54 | 1134 | 3.737e-05 | 0.002728 |
9 | CYTOSKELETON | 80 | 1967 | 0.0001295 | 0.006876 |
10 | CELL CELL JUNCTION | 24 | 383 | 0.0001279 | 0.006876 |
11 | PLASMA MEMBRANE RAFT | 10 | 86 | 0.0001065 | 0.006876 |
12 | SARCOLEMMA | 12 | 125 | 0.000147 | 0.007042 |
13 | MAIN AXON | 8 | 58 | 0.0001568 | 0.007042 |
14 | CELL SURFACE | 38 | 757 | 0.0001946 | 0.008117 |
Num | Pathway | Pathview | Overlap | Size | P Value | Adj. P Value |
---|---|---|---|---|---|---|
1 | MAPK_signaling_pathway_hsa04010 | 23 | 295 | 5.854e-06 | 0.0003044 | |
2 | FoxO_signaling_pathway_hsa04068 | 13 | 132 | 6.036e-05 | 0.001569 | |
3 | Focal_adhesion_hsa04510 | 16 | 199 | 0.0001056 | 0.00183 | |
4 | TNF_signaling_pathway_hsa04668 | 11 | 108 | 0.0001631 | 0.00212 | |
5 | Signaling_pathways_regulating_pluripotency_of_stem_cells_hsa04550 | 12 | 139 | 0.0003957 | 0.00377 | |
6 | TGF_beta_signaling_pathway_hsa04350 | 9 | 84 | 0.0004351 | 0.00377 | |
7 | Hippo_signaling_pathway_multiple_species_hsa04392 | 5 | 29 | 0.0009779 | 0.00665 | |
8 | Endocytosis_hsa04144 | 16 | 244 | 0.001023 | 0.00665 | |
9 | ECM_receptor_interaction_hsa04512 | 8 | 82 | 0.001659 | 0.009584 | |
10 | Oocyte_meiosis_hsa04114 | 10 | 124 | 0.001978 | 0.01028 | |
11 | Gap_junction_hsa04540 | 8 | 88 | 0.0026 | 0.01169 | |
12 | mTOR_signaling_pathway_hsa04150 | 11 | 151 | 0.002697 | 0.01169 | |
13 | Hippo_signaling_pathway_hsa04390 | 11 | 154 | 0.00314 | 0.01256 | |
14 | Regulation_of_actin_cytoskeleton_hsa04810 | 13 | 208 | 0.004412 | 0.01639 | |
15 | Rap1_signaling_pathway_hsa04015 | 12 | 206 | 0.01041 | 0.03278 | |
16 | Ras_signaling_pathway_hsa04014 | 13 | 232 | 0.01066 | 0.03278 | |
17 | Calcium_signaling_pathway_hsa04020 | 11 | 182 | 0.01072 | 0.03278 | |
18 | Apoptosis_hsa04210 | 9 | 138 | 0.0127 | 0.03628 | |
19 | cGMP_PKG_signaling_pathway_hsa04022 | 10 | 163 | 0.01325 | 0.03628 | |
20 | Cytokine_cytokine_receptor_interaction_hsa04060 | 14 | 270 | 0.01543 | 0.03848 | |
21 | PI3K_Akt_signaling_pathway_hsa04151 | 17 | 352 | 0.01557 | 0.03848 | |
22 | Cell_adhesion_molecules_.CAMs._hsa04514 | 9 | 145 | 0.01706 | 0.03848 | |
23 | Tight_junction_hsa04530 | 10 | 170 | 0.01732 | 0.03848 | |
24 | Wnt_signaling_pathway_hsa04310 | 9 | 146 | 0.01776 | 0.03848 | |
25 | Ferroptosis_hsa04216 | 4 | 40 | 0.0223 | 0.04638 | |
26 | p53_signaling_pathway_hsa04115 | 5 | 68 | 0.03657 | 0.07314 | |
27 | Sphingolipid_signaling_pathway_hsa04071 | 7 | 118 | 0.04099 | 0.07894 | |
28 | cAMP_signaling_pathway_hsa04024 | 10 | 198 | 0.04302 | 0.0799 | |
29 | Phospholipase_D_signaling_pathway_hsa04072 | 8 | 146 | 0.04476 | 0.08026 | |
30 | Phagosome_hsa04145 | 8 | 152 | 0.05433 | 0.09418 | |
31 | Autophagy_animal_hsa04140 | 7 | 128 | 0.05875 | 0.09855 | |
32 | Cellular_senescence_hsa04218 | 8 | 160 | 0.069 | 0.1121 | |
33 | Apelin_signaling_pathway_hsa04371 | 7 | 137 | 0.07825 | 0.1224 | |
34 | ErbB_signaling_pathway_hsa04012 | 5 | 85 | 0.08001 | 0.1224 | |
35 | Phosphatidylinositol_signaling_system_hsa04070 | 5 | 99 | 0.1299 | 0.1878 | |
36 | Adherens_junction_hsa04520 | 4 | 72 | 0.13 | 0.1878 | |
37 | HIF_1_signaling_pathway_hsa04066 | 5 | 100 | 0.1339 | 0.1882 | |
38 | Jak_STAT_signaling_pathway_hsa04630 | 7 | 162 | 0.1496 | 0.2047 | |
39 | Necroptosis_hsa04217 | 7 | 164 | 0.1563 | 0.2084 | |
40 | Peroxisome_hsa04146 | 4 | 83 | 0.1863 | 0.2422 | |
41 | VEGF_signaling_pathway_hsa04370 | 3 | 59 | 0.2132 | 0.2704 | |
42 | Apoptosis_multiple_species_hsa04215 | 2 | 33 | 0.2236 | 0.2769 | |
43 | AMPK_signaling_pathway_hsa04152 | 5 | 121 | 0.2292 | 0.2771 | |
44 | NF_kappa_B_signaling_pathway_hsa04064 | 4 | 95 | 0.2549 | 0.3012 | |
45 | ABC_transporters_hsa02010 | 2 | 45 | 0.3439 | 0.3974 | |
46 | Notch_signaling_pathway_hsa04330 | 2 | 48 | 0.3733 | 0.422 | |
47 | Lysosome_hsa04142 | 4 | 123 | 0.4255 | 0.4707 | |
48 | Cell_cycle_hsa04110 | 3 | 124 | 0.6546 | 0.7091 | |
49 | Neuroactive_ligand_receptor_interaction_hsa04080 | 6 | 278 | 0.7649 | 0.7955 |